PTC Therapeutics, Inc. (NASDAQ:PTCT) was the target of some unusual options trading activity on Wednesday. Stock traders bought 3,043 put options on the stock. This is an increase of 2,154% compared to the average volume of 135 put options.
In other news, CEO Stuart Walter Peltz sold 2,230 shares of the stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $18.03, for a total transaction of $40,206.90. Following the sale, the chief executive officer now directly owns 26,646 shares of the company’s stock, valued at $480,427.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 2,719 shares of company stock worth $48,848 over the last three months. 8.10% of the stock is owned by insiders.
A number of hedge funds have recently made changes to their positions in PTCT. Macquarie Group Ltd. bought a new position in shares of PTC Therapeutics during the third quarter worth $102,000. Public Employees Retirement System of Ohio bought a new position in shares of PTC Therapeutics during the second quarter worth $142,000. Quantbot Technologies LP bought a new position in shares of PTC Therapeutics during the third quarter worth $150,000. Prudential Financial Inc. bought a new position in shares of PTC Therapeutics during the second quarter worth $201,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of PTC Therapeutics during the third quarter worth $229,000. 86.12% of the stock is currently owned by hedge funds and other institutional investors.
PTC Therapeutics (PTCT) opened at $23.29 on Friday. PTC Therapeutics has a 52 week low of $8.12 and a 52 week high of $23.71. The stock has a market cap of $966.29, a P/E ratio of -8.06 and a beta of 1.23. The company has a quick ratio of 2.97, a current ratio of 3.08 and a debt-to-equity ratio of 0.98.
About PTC Therapeutics
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.